Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics -- Data Supplement - Supplemental Data -- Proceedings of the National Academy of Sciences

Supplementary material for Virtaneva et al. (2001) Proc. Natl. Acad. Sci. USA 98 (3), 1124–1129. (10.1073/pnas.031566698)

Supplemental Figure 7 Fig. 7.
Independent verification of GeneChip expression quantification with the TaqMan 5' nuclease assay. From 60 genes dysregulated in the AML+8 vs. AML-CN comparison, 11 representative genes were chosen for independent verification on the basis of their strong ability to discriminate AML+8 from AML-CN in the GeneChip assay. Transcript levels were quantified for four genes upregulated in AML+8 (FABP5, ATF4, MIF, and SIAHBP1) and four genes upregulated in AML-CN (PBX3, MLLT2, PTEN, and CRADD), as well as MPO, FUS, and CD34, using 6 AML+8 and 5 AML-CN bone marrow samples. Values from both analyses were normalized to an endogenous control (ACTB) and plotted. Sample data points for the two strongest discriminators in both assays, MLLT2 and FABP5, are shown for AML+8 (filled squares, filled circles) and AML-CN (open squares, open circles) samples. Results for the GeneChip assay (filled circles, open circles) are shown against the left-hand scale and those for the TaqMan assay (filled squares, open squares) against the right-hand scale. The P values indicate the power of the two sample means (+8 vs. CN) to distinguish between the two samples sets for either the GeneChip or TaqMan assay.